Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae

Microbial Pathogenesis

Volumn 40, Issue 5, 2006, Pages 228-233

  Daniels, Calvin C ^a   Briles, Travis C ^a   Mirza, Shaper ^a   Håkansson, Anders P ^b,c   Briles, David E ^a,d  

^a University of Alabama at Birmingham   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Capsule; Phosphocholine; Pneumococcal surface protein A; Streptococcus pneumoniae

Indexed keywords

BACTERIAL PROTEIN; CELL SURFACE PROTEIN; EPITOPE; LIPOTEICHOIC ACID; MONOCLONAL ANTIBODY; PHOSPHORYLCHOLINE; PNEUMOCOCCAL SURFACE PROTEIN A; POLYSACCHARIDE; TEICHOIC ACID; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL SURFACE; CONTROLLED STUDY; DATA ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; STREPTOCOCCUS PNEUMONIAE;

ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MUTATION; PHOSPHORYLCHOLINE; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VIRULENCE;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

EID: 33646251599     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2006.01.007     Document Type: Article

References (47)

1. Fraser D.W. What are our bacterial disease problems. In: Robbins J.B., Hill J.C., and Sadoff J.C. (Eds) (1982), Bacterial Vaccines, New York xix-xxiv
2. Fedson D.S., Anthony J., and Scott G. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17 Suppl. 1 (1999) S11-S18
3. Fedson D.S., and Musher D.M. Pneumococcal polysaccharide vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines (2004), Saunders, Philadelphia, PA 529-588
4. Eskola J., Black S., and Shinefield H. Pneumococcal conjugate vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines (2004), Saunders, Philadelphia, PA 589-624
5. Briles D.E., Paton J.C., and Hollingshead S.K. Pneumococcal common proteins and other vaccine strategies. In: Levine M.M., Kaper J.B., Rappuoli R., Liu M., and Good M.F. (Eds). New generation vaccines. 3rd ed (2004), Marcel Dekker, New York, NY 459-469
6. Jedrzejas M.J. Extracellular virulence factors of Streptococcus pneumoniae. Front Biosci 9 (2004) 891-914
7. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68 2 (2000) 796-800
8. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., et al. Immunization of humans with rPspA elicits antibodies, which passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182 (2000) 1694-1701
9. Briles D.E., Hollingshead S.K., Paton J.C., Ades E.W., Novak L., van Ginkel F.W., et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188 3 (2003) 339-348
10. McDaniel L.S., Yother J., Vijayakumar M., McGarry L., Guild W.R., and Briles D.E. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 165 (1987) 381-394
11. Ren B., Szalai A.J., Thomas O., Hollingshead S.K., and Briles D.E. Both family 1 and family 2 PspAs can inhibit complement deposition and confer virulence to a capsular 3 serotype Streptococcus pneumoniae. Infect Immun 71 (2003) 75-85
12. Yother J., and Briles D.E. Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol 174 (1992) 601-609
13. Yother J., Handsome G.L., and Briles D.E. Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol 174 (1992) 610-618
14. Yother J., and White J.M. Novel surface attachment mechanism for the Streptococcus pneumoniae protein PspA. J Bacteriol 176 (1994) 2976-2985
15. McDaniel L.S., McDaniel D.O., Hollingshead S.K., and Briles D.E. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect Immun 66 (1998) 4748-4754
16. Hollingshead S.K., Becker R.S., and Briles D.E. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68 (2000) 5889-5900
17. McDaniel L.S., Ralph B.A., McDaniel D.O., and Briles D.E. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 17 (1994) 323-337
18. Roche H., Hakansson A., Hollingshead S.K., and Briles D.E. Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun 71 3 (2003) 1033-1041
19. Ren B., Szalai A.J., Hollingshead S.K., and Briles D.E. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72 (2004) 114-122
20. Mirza S., Hollingshead S.K., Benjamin Jr. W.H., and Briles D.E. PspA protects Streptococcus pneumoniae from killing by apolactoferrin and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect Immun 72 9 (2004) 5031-5040
21. Yother J. Capsules. In: Tuomanen E.I., Mitchell T.J., Morrison D.A., and Spratt B.G. (Eds). The pneumococcus (2004), ASM Press, Washington, DC 30-48
22. McDaniel L.S., Scott G., Widenhofer K., Carroll J., and Briles D.E. Analysis of a surface protein of Streptococcus pneumoniae recognized by protective monoclonal antibodies. Microb Pathog 1 (1986) 519-531
23. Hakansson A., Roche H., Mirza S., McDaniel L.S., Brooks-Walter A., and Briles D.E. Characterization of the binding of human lactoferrin to pneumococcal surface protein A (PspA). Infect Immun 69 (2001) 3372-3381
24. Swiatlo E., King J., Nabors G.S., Mathews B., and Briles D.E. Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis. Infect Immun 71 12 (2003) 7149-7153
25. Yother J., Forman C., Gray B.M., and Briles D.E. Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun 36 (1982) 184-188
26. Abeyta M., Hardy G.G., and Yother J. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun 71 1 (2003) 218-225
27. Briles D.E., Forman C., Horowitz J.C., Volanakis J.E., Benjamin Jr. W.H., McDaniel L.S., et al. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun 57 (1989) 1457-1464
28. Briles D.E., Tart R.C., Wu H.-Y., Ralph B.A., Russell M.W., and McDaniel L.S. Systemic and mucosal protective immunity to pneumococcal surface protein A. NY Acad Sci USA 797 (1996) 118-126
29. Fischetti V.A. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 2 (1989) 258-314
30. Jedrzejas M.J., Hollingshead S.K., Lebowitz J., Chantalat L., Briles D.E., and Lamani E. Production and characterization of the functional fragment of pneumococcal surface protein A. Arch Biochem Biophys 373 1 (2000) 116-125
31. Briles D.E., Paton J.C., Nahm M.H., and Swiatlo E. Immunity to Streptococcus pneumoniae. In: Cunningham M., and Fujinami R.S. (Eds). Effect of microbes on the immune system (2000), Lippincott-Raven, Philadelphia, PA 263-280
32. Sorensen U.B.S., Blom J., Birch-Andersen A., and Henrichsen J. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F-antigen in pneumococci. Infect Immun 56 (1988) 1890-1896
33. Fischer W. Teichoic acid and lipoblycans. New Compr Biochem 27 (1994) 199-215
34. Briles D.E., Nahm M., Schroer K., Davie J., Baker P., Kearney J., et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J Exp Med 153 (1981) 694-705
35. Briles D.E., Forman C., and Crain M. Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun 60 (1992) 1957-1962
36. Mi Q.S., Zhou L., Schulze D.H., Fischer R.T., Lustig A., Rezanka L.J., et al. Highly reduced protection against Streptococcus pneumoniae after deletion of a single heavy chain gene in mouse. Proc Natl Acad Sci USA 97 11 (2000) 6031-6036
37. Goldenberg H.B., McCool T.L., and Weiser J.N. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis 190 7 (2004) 1254-1263
38. Tu A.-H.T., Fulgham R.L., McCory M.A., Briles D.E., and Szalai A.J. Pneumococcal surface protein A (PspA) inhibits complement activation by Streptococcus pneumoniae. Infect Immun 67 (1999) 4720-4724
39. Avery O.T., MacLeod C.M., and McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 79 (1944) 137-158
40. Magee A.D., and Yother J. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun 69 6 (2001) 3755-3761
41. Dillard J.P., and Yother J. Genetic and molecular characterization of capsular polysaccharide biosynthesis in Streptococcus pneumoniae type 3. Mol Microbiol 12 (1994) 959-972
42. McDaniel L.S., Ralph B.A., McDaniel D.O., and Briles D.E. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 17 5 (1994) 323-337
43. Crain M.J., Waltman W.D., Turner J.S., Yother J., Talkington D.E., McDaniel L.M., et al. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun 58 (1990) 3293-3299
44. Waltman W.D., Gray B., McDaniel L.S., and Briles D.E. Cross-reactive monoclonal antibodies for diagnosis of pneumococcal meningitis. J Clin Microbiol 26 (1988) 1635-1640
45. Vela Coral M.C., Fonseca N., Castaneda E., Di Fabio J.L., Hollingshead S.K., and Briles D.E. Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis 7 5 (2001) 832-836
46. Zar JH. Regression analysis. In: Biostatistical analysis. 2nd ed. Englewood Cliffs, NJ: Printice-Hall; 1984. p. 103-8.
47. Shoemaker N.B., and Guild W.R. Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation. Mol Gen Genet 128 (1974) 283-290